Xeris Biopharma(XERS) - 2025 Q1 - Quarterly Results

Exhibit 99.1 XERIS BIOPHARMA REPORTS RECORD FIRST QUARTER 2025 FINANCIAL RESULTS Total revenue increased 48% YoY to over $60 million Recorlev® revenue grew 141% on YoY basis Tightens full-year total revenue 2025 guidance to $260 million to $275 million Announces upcoming Investor and Analyst Day on June 3 in New York City rd Hosts conference call and webcast today at 8:30 a.m. ET CHICAGO, IL (BUSINESS WIRE); May 8, 2025 – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical compan ...